Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Fleming
Thomas
T
Borer
Jeff
J
Armstrong
Paul W
PW
Pfeffer
Marc
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists; D001262:Atenolol / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D017277:Drug Approval; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D044469:Racial Groups / Q000235:genetics; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D044140:Receptor, Angiotensin, Type 1; D012084:Renin-Angiotensin System / Q000235:genetics; D012306:Risk; D020521:Stroke / Q000517:prevention & control; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000592:standards
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D002227:Carbazoles; D011412:Propanolamines; D044140:Receptor, Angiotensin, Type 1; D000077261:Carvedilol; D001262:Atenolol; D019808:Losartan